Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Khushwant S. Yadav, Hrushikesh C. Raut & Harsh P. Nijhawan. (2023) Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells. Pharmaceutical Development and Technology 28:8, pages 755-767.
Read now
Read now
Marybeth Sechler, Amber D Cizmic, Sreedevi Avasarala, Michelle Van Scoyk, Christine Brzezinski, Nicole Kelley, Rama Kamesh Bikkavilli & Robert A Winn. (2013) Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmacogenomics and Personalized Medicine 6, pages 25-36.
Read now
Read now
Anja K Weidemann, Ania A Crawshaw, Emily Byrne & Helen S Young. (2013) Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology 6, pages 233-244.
Read now
Read now
Articles from other publishers (18)
Masoumeh Eliyasi Dashtaki & Sorayya Ghasemi. (2023) Anti-angiogenic Drug Resistance: Roles and Targeting of Non-coding
RNAs (microRNAs and long non-coding RNAs). Current Molecular Pharmacology 16:8.
Crossref
Crossref
Hongyu Kong, Rong Zhang, Qinghe Jing, Yu Liang, Qiao Zhuo, Bo Li, Shujie Zhang, Weiliang Zhu & Chen Zhao. (2022) Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT/ERK1/2 pathway. Microvascular Research 143, pages 104401.
Crossref
Crossref
Sangmin Jung, Hyeonsu Jo, Sujin Hyung & Noo Li Jeon. 2022. Microfluidics and Biosensors in Cancer Research. Microfluidics and Biosensors in Cancer Research
231
256
.
Xinliang Gao, Mingbo Tang, Suyan Tian, Jialin Li & Wei Liu. (2021) A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma. Future Oncology 17:12, pages 1533-1544.
Crossref
Crossref
Shanshan Jiang, Rong Wang, Xuan Zhang, Feihua Wu, Shengnan Li & Yongfang Yuan. (2020) Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in�vitro and in�vivo via the epithelial‑to‑mesenchymal transition process. Oncology Letters.
Crossref
Crossref
Edward Hammond & Keith Dredge. 2020. Heparanase. Heparanase
539
565
.
Huimin Luo, Jianxin Wang, Min Li, Junwei Luo, Peng Ni, Kaijie Zhao, Fang-Xiang Wu & Yi Pan. (2019) Computational Drug Repositioning with Random Walk on a Heterogeneous Network. IEEE/ACM Transactions on Computational Biology and Bioinformatics 16:6, pages 1890-1900.
Crossref
Crossref
Manpreet Sambi & Myron R. Szewczuk. 2019. Current Applications for Overcoming Resistance to Targeted Therapies. Current Applications for Overcoming Resistance to Targeted Therapies
1
33
.
Dexiang Yang, Ranran Dai, Qi Zhang & Ping Fang. (2018) Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi Journal of Biological Sciences 25:5, pages 888-894.
Crossref
Crossref
Glenwood Goss & Tony Mok. 2018. IASLC Thoracic Oncology. IASLC Thoracic Oncology
434
447.e5
.
Justyna Kutkowska, Leon Strzadala & Andrzej Rapak. (2017) Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non‐small cell lung cancer cells. Cancer Science 108:11, pages 2265-2272.
Crossref
Crossref
Zhihao Wang, Pengchao Hu, Fang Tang & Conghua Xie. (2016) HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. Medical Oncology 33:5.
Crossref
Crossref
Jia-Nian Chen, Xian-Fu Wang, Ting Li, De-Wen Wu, Xiao-Bo Fu, Guang-Ji Zhang, Xing-Can Shen & Heng-Shan Wang. (2016) Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents. European Journal of Medicinal Chemistry 107, pages 12-25.
Crossref
Crossref
Yanmei Zhang, Micky D. Tortorella, Jinxi Liao, Xiaochu Qin, Tingting Chen, Jinfeng Luo, Jiantong Guan, John J. Talley & Zhengchao Tu. (2015) Synthesis and Evaluation of Novel Erlotinib–NSAID Conjugates as More Comprehensive Anticancer Agents. ACS Medicinal Chemistry Letters 6:10, pages 1086-1090.
Crossref
Crossref
Ashraf Kareem El-Damasy, Seon Hee Seo, Nam-Chul Cho, Soon Bang Kang, Ae Nim Pae, Key-Sun Kim & Gyochang Keum. (2015) Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives. European Journal of Medicinal Chemistry 101, pages 754-768.
Crossref
Crossref
Sarah Fernandes Teixeira, Ricardo Alexandre de Azevedo, Maria Alejandra Clavijo Salomon, Salomão Dória Jorge, Débora Levy, Sérgio Paulo Bydlowski, Cecília Pessoa Rodrigues, Célia Regina Pizzo, José Alexandre Marzagão Barbuto & Adilson Kleber Ferreira. (2014) Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomedicine & Pharmacotherapy 68:8, pages 1015-1022.
Crossref
Crossref
Neelesh Sharma, Nathan Pennell, Myles Nickolich, Balazs Halmos, Patrick Ma, Tarek Mekhail, Pingfu Fu & Afshin Dowlati. (2014) Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Investigational New Drugs 32:2, pages 362-368.
Crossref
Crossref
J Wan, T Liu, L Mei, J Li, K Gong, C Yu & W Li. (2013) Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling. British Journal of Cancer 109:2, pages 342-350.
Crossref
Crossref